Chemotherapy Compounding

Slade Health opens first-of-its-kind Australian research lab

Icon changes the face of compounding in New Zealand

Slade partners with Can Assist to support cancer patients in rural and regional communities

Slade Health expands services

Slade Health awarded sole supplier of compounded pharmaceuticals in South Australia public hospitals

Cutting-edge equipment brings care closer to Mackay homes

Isolator allows medications to be manufactured on-site to deliver care close to home.

New investors for Icon Group

Goldman Sachs Principal Investment Area (GS PIA), QIC and Pagoda Investments acquires Icon.

Slade Health broadens into antibiotic compounding

Acquisition of antibiotic compounding business mobiLIFE.

Icon Group joins new initiative as a founding partner to change the future of cancer in urban populations

Fighting the global cancer burden with Union for International Control